Sam Brusco, Associate Editor05.03.22
The Medical Device Manufacturers Association (MDMA) appointed Outset Medical chair and CEO Leslie Trigg as its new board chair during the organization’s 2022 annual meeting where medical technology executives heard from HHS Secretary Xavier Becerra, CMS chief medical officer Dr. Lee Fleisher, Senators Amy Klobuchar and Todd Young, Representatives Anna Eshoo and Suzan DelBene, and many more.
She follows the three-year tenure of Avalign Technologies CEO Jeff McCaulley, who oversaw the medical device tax’s full repeal and the MDUFA V negotiations. Trigg highlighted the significance of shortening the gap between the regulatory process and gaining reimbursement, as well as successful MDUFA V implementation as the board’s top priorities over the next few years.
“Medical technology innovators are at the forefront of improving patient outcomes and reducing the cost of care, and I am honored to lead MDMA as they continue their tremendous work as the leading voice of our industry,” Trigg told the press. “Modern technology is impacting when, where and how healthcare can be delivered. Together, we have the privilege of imagining what the future of healthcare could look like, and turning invention into reality.”
“For 30 years, MDMA has been dedicated to serving innovative and entrepreneurial medical technology companies, and this dynamic ecosystem is poised to solve some of the most pressing issues facing patient care in the years to come,” said Mark Leahey, president and CEO of MDMA. “Leslie is an amazing leader whose vision will help guide MDMA and our industry over the challenges and opportunities facing the delivery of healthcare in the 21st century.”
She follows the three-year tenure of Avalign Technologies CEO Jeff McCaulley, who oversaw the medical device tax’s full repeal and the MDUFA V negotiations. Trigg highlighted the significance of shortening the gap between the regulatory process and gaining reimbursement, as well as successful MDUFA V implementation as the board’s top priorities over the next few years.
“Medical technology innovators are at the forefront of improving patient outcomes and reducing the cost of care, and I am honored to lead MDMA as they continue their tremendous work as the leading voice of our industry,” Trigg told the press. “Modern technology is impacting when, where and how healthcare can be delivered. Together, we have the privilege of imagining what the future of healthcare could look like, and turning invention into reality.”
“For 30 years, MDMA has been dedicated to serving innovative and entrepreneurial medical technology companies, and this dynamic ecosystem is poised to solve some of the most pressing issues facing patient care in the years to come,” said Mark Leahey, president and CEO of MDMA. “Leslie is an amazing leader whose vision will help guide MDMA and our industry over the challenges and opportunities facing the delivery of healthcare in the 21st century.”